Oral rabeprazole vs. intravenous pantoprazole: A comparison of the effect on intragastric pH in healthy subjects

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 2, 2007, Pages 185-196

  Armstrong, D ^a,b   James, C ^b   Camacho, F ^c   Chen, Y ^b   Horbay, G L A ^d   Teixeira, B ^d   Husein Bhabha, F A ^d  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DAMOS Inc   (Canada)

^d Janssen Ortho Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE; RABEPRAZOLE;

ACIDITY; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA COLLECTION METHOD; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTRIC PH MONITORING; HELICOBACTER PYLORI; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH SECRETION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; ANTACIDS; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE;

EID: 33846023335     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03160.x     Document Type: Article

References (37)

1. Freston J, Chiu YL, Pan WJ, Lukasik N, Täubel J. Effect on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole, administered intravenously. Am J Gastroenterol 2001; 96: 2058-65.
2. Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology 1992; 39: 322-4.
3. Sanders SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 1996; 18: 2-34; discussion 1.
4. Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
5. Garnett WR. History of acid suppression: focus on the hospital setting. Pharmacotherapy 2003; 23 (10 Pt 2): 56S-60S.
6. Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med 2002; 30 (Suppl. 6): S356-61.
7. Barkun A, Bardou M, Marshall JK. Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 843-57.
8. Morgan D. Intravenous proton pump inhibitors in the critical care setting. Crit Care Med 2002; 30 (Suppl. 6): S369-72.
9. PANTO®. IV (Pantoprazole Sodium for Injection) Monograph. Germany: ALTANA Pharma AG (version 10 February 1999; revised 30 July 2002).
10. Trepanier EF. Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. Can J Gastroenterol 2000; 14 (Suppl. D): 11D-20D.
11. Enns R, Andrews CN, Fishman M, et al. Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre evaluation. Can J Gastroenterol 2004; 18: 567-71.
12. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25-33.
13. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
14. Tutuian R, Castell DO, Xue S, Katz PO. The acidity index: a simple approach to the measurement of gastric acidity. Aliment Pharmacol Ther 2004; 19: 443-8.
15. Shih GL, Brensinger CM, Katzka DA, Metz DC. Postprandial oesophageal integrated acidity is a reliable predictor of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 21: 1475-82.
16. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994; 8 (Suppl. 1): 39-46.
17. Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998; 12: 1027-32.
18. Metz DC, Pratha V, Martin P, et al. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 626-33.
19. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14.
20. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
21. Good Clinical Practice: Consolidated Guidelines of the International Conference on Harmonization Topic E6. Ottawa: Therapeutic Products Directorate, Health Canada. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide- ld/ich/efficac/e6_e.html. Last accessed 5 October 2006.
22. 13C urea breath test for Helicobacter pylori: determination of the optimal cut-off point in a Canadian community population. Can J Gastroenterol 2006; 20: 770-4.
23. Warrington S, Lee D, Baisley K, DeLemos B, Lomax K, Morocutti A. Effect of Single Doses of Rabeprazole 20 mg and Pantoprazole 40 mg on 24-hour Intragastric Acidity in Gastroesophageal Reflux Disease Patients with Nocturnal Heartburn. Montreal, Canada: Abstract presented at World Congress of Gastroenterology, 2005. Can J Gastroenterol 2005; 19(Suppl. C): R0054.
24. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-7.
25. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11.
26. Bianchi Porro G, Pace F. Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000; 12 (Suppl. 1): S7-10.
27. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46.
28. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
29. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997; 41: 277-80.
30. Thomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481-91.
31. Enns R. Less acid + less bleeding = better outcomes and more money! Can J Gastroenterol 2004; 18: 747-8.
32. Kaplan GG, Bates D, McDonald D, Panaccione R, Romagnuolo J. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol 2005; 3: 1207-14.
33. Katz PO, Ginsberg GG, Hoyle P, Sostek MB, Monyak J, Silberg DG. Positive association between intragastric and intraesophageal acid control and healing of Los Angeles Grade C and D erosive esophagitis: results of a prospective, controlled clinical trial. Gastroenterology 2006; 130 (Suppl. 2): A14 (Abstract 69).
34. Wurzer H, Schutze K, Bethke T, Fischer R, Luhmann R, Riesenhuber C. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology 1999; 46: 1809-15.
35. Cloud MI, Enas N, Humphries TJ, Bassion S. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and gastro-esophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 1998; 43: 993-1000.
36. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with Rabeprazole 10 or 20 mg vs. placebo: results of a 5 year study in the United States. Aliment Pharmacol Ther 2005; 22: 193-202.
37. Birbara C, Breiter J, Perdomo C, Hahne W. Rabeprazole for the prevention of recurrent erosive or ulcerative gastrooesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol 2000; 12: 889-97.